The Pleitropic Drug ABC Transporters from Saccharomyces Cerevisiae

Total Page:16

File Type:pdf, Size:1020Kb

The Pleitropic Drug ABC Transporters from Saccharomyces Cerevisiae J. Mol. Microbiol. Biotechnol. (2001) 3(2): 207-214. Drug ABC TransportersJMMB from S. Symposium cerevisiae 207 The Pleitropic Drug ABC Transporters from Saccharomyces cerevisiae Bruce Rogers1,3, Anabelle Decottignies2,4, The Discovery of the Yeast ABC Transporters and of Marcin Kolaczkowski2,5, Elvira Carvajal2,6, their Major Regulators Elisabetta Balzi2,7and André Goffeau2,8,* The first ABC transporter gene discovered in 1Phytera Inc, Worcester, MA, USA Saccharomyces cerevisiae was shown to encode the full- 2Unité de biochimie physiologique, Louvain-la-Neuve, size Ste6p plasma membrane protein exporting the a- Belgium mating pheromone (Mcgrath and Varshafsky, 1989; Kuchler 3Present address: Genetics Institute, Inc., Cambridge, MA, et al., 1989,). The first half-size ABC transporter gene, USA ADP1, was unravelled by the systematic sequencing of 4Present address: Imperial Cancer Research Fund, chromosome III (Purnelle et al., 1991). Adp1p belongs to London, U.K. the historic “white” family determining the eye color of 5Present address: University of Medicine Wroclaw, Drosophila. Its function in yeast is still unknown today. Department of Biophysics, Wroclaw, Poland During the next few “pregenomic” years, four additional 6Present address: State University of Rio de Janeiro, transporters were reported. The SNQ2 gene was Dept. Cell Biology and Genetics., Rio Janeiro, Brazil discovered in a screen for mutants resistant to 7Present address: European Commission, Research nitroxiquinoline oxides and other mutagens (Servos et al., Directorate, Brussels, Belgium 1993). The overexpressed PDR5 gene was found to confer 8Present address: Chaire Internationale de Recherche resistance to cycloheximide and many other drugs (Balzi Blaise Pascal, Laboratoire de Biologie Moléculaire, Ecole et al., 1994; Bissinger et al., 1994; Hirata et al., 1994). The Normale Supérieure, Paris, France YCF1 gene was detected as responsible for a cadmium resistance phenotype due to accumulation of glutathione- heavy metal conjugates in vacuole (Szczypka et al.,1994, Abstract Li et al., 1996 ). The mutated YOR1 gene was reported as conferring oligomycin and anionic drugs sensitivity The Saccharomyces cerevisiae genome contains 16 (Katzmann et al., 1995, Cui et al., 1996). genes encoding full-size ABC transporters. Each comprises two nucleotide binding folds (NBF) alternating with transmembrane domains (TM). We have studied in detail three plasma membrane multidrug exporters: Pdr5p (TC3.A.1.205.1) and Snq2p Table 1. The yeast ABC transporters according to the Transporter (TC3.A.1.205.2) which share NBF-TM-NBF-TM topology Classification (TC) system (Saier, 2000) as well as Yor1p (TC3.A.1.208.3) which exhibits the 3.A.1.203 The Peroxysomal Fatty Acyl CoA Transporter (FAT) reciprocal TM-NBF-TM-NBF topology. The substrate Family specificity of Pdr5p, Snq2p and Yor1p are largely, but 3.A.1.203.2 PAT1/PAL1/PXA1 and PAT2/PAL2/PXA2: long chain not totally, overlapping as shown by screening the fatty acyl COA importer 3.A.1.204 The Eye Pigment Precursor Transporter (EPP) Family growth inhibition by 349 toxic compounds of undetermined ADP1: unknown substrate combinatorial deletants of these three ABC genes. 3.A.1.205 The Pleiotropic Drug Resistance (PDR) Family Multiple deletion of 7 ABC genes (YOR1, SNQ2, PDR5, 3.A.1.205.1 PDR5: cycloheximide/pleiotropic drug exporter 3.A.1.205.2 SNQ2: mutagen/pleiotropic drug exporter YCF1, PDR10, PDR11 and PDR15) and of two 3.A.1.205.3 PDR12: weak acid exporter. transcription activation factors (PDR1 and PDR3) undetermined PDR10, PDR15 and YOR011: unknown substrates. renders the cell from 2 to 200 times more sensitive to 3.A.1.206 The Sex Pheromone Exporter (STE) Family numerous toxic coumpounds including antifungals 3.A.1.206.1 STE6: a-factor sex pheromone exporter 3.A.1.207 The Conjugate Transporter (CT1) Family used in agriculture or medicine. The use of the pdr1-3 3.A.1.207.1 YCF1: vacuolar metal resistance factor activating mutation and when necessary of the PDR5 3.A.1.207.2 BAT1: vacuolar bile acid transporter promoter in appropriate multideleted hosts allow high 3.A.1.207.3 BPT1: vacuolar bilirubin transporter undetermined YHL035: unknown substrate levels of expression of Pdr5p, Snq2p or Yor1p. These 3.A.1.208 The Conjugate Transporter (CT2) Family overexpressed proteins exhibit ATPase activity in vitro 3.A.1.208.3 YOR1: oligomycin/pleiotropic drug exporter and confer considerable multiple drug resistance in 3.A.1.209 The Major Histocompatibility Peptide Transporter vivo. The latter property can be used for screening (TAP) Family undetermined TAP1/TAP2: unknown substrate specific inhibitors of fungal and other ABC 3.A.1.212 The Mitochondrial Fe/S Protein Exporter (MPE) transporters. Family 3.A.1.212.1 ATM1: mitochondrial putative iron transporter 3.A.1.213 The Putative Transporter Family of Unknown Function 3.A.1.213.1 PDR11 and YOR011: unknown function 3.A.1.213.2 YOL075: unknown function *For correspondence. Email [email protected]. 3.A.1.213.3 MDL1 and MDL2: unknown function © 2001 Horizon Scientific Press Further Reading Caister Academic Press is a leading academic publisher of advanced texts in microbiology, molecular biology and medical research. Full details of all our publications at caister.com • MALDI-TOF Mass Spectrometry in Microbiology Edited by: M Kostrzewa, S Schubert (2016) www.caister.com/malditof • Aspergillus and Penicillium in the Post-genomic Era Edited by: RP Vries, IB Gelber, MR Andersen (2016) www.caister.com/aspergillus2 • The Bacteriocins: Current Knowledge and Future Prospects Edited by: RL Dorit, SM Roy, MA Riley (2016) www.caister.com/bacteriocins • Omics in Plant Disease Resistance Edited by: V Bhadauria (2016) www.caister.com/opdr • Acidophiles: Life in Extremely Acidic Environments Edited by: R Quatrini, DB Johnson (2016) www.caister.com/acidophiles • Climate Change and Microbial Ecology: Current Research and Future Trends Edited by: J Marxsen (2016) www.caister.com/climate • Biofilms in Bioremediation: Current Research and Emerging Technologies • Flow Cytometry in Microbiology: Technology and Applications Edited by: G Lear (2016) www.caister.com/biorem Edited by: MG Wilkinson (2015) www.caister.com/flow • Microalgae: Current Research and Applications • Probiotics and Prebiotics: Current Research and Future Trends Edited by: MN Tsaloglou (2016) www.caister.com/microalgae Edited by: K Venema, AP Carmo (2015) www.caister.com/probiotics • Gas Plasma Sterilization in Microbiology: Theory, Applications, Pitfalls and New Perspectives • Epigenetics: Current Research and Emerging Trends Edited by: H Shintani, A Sakudo (2016) Edited by: BP Chadwick (2015) www.caister.com/gasplasma www.caister.com/epigenetics2015 • Virus Evolution: Current Research and Future Directions • Corynebacterium glutamicum: From Systems Biology to Biotechnological Applications Edited by: SC Weaver, M Denison, M Roossinck, et al. (2016) www.caister.com/virusevol Edited by: A Burkovski (2015) www.caister.com/cory2 • Arboviruses: Molecular Biology, Evolution and Control Edited by: N Vasilakis, DJ Gubler (2016) • Advanced Vaccine Research Methods for the Decade of www.caister.com/arbo Vaccines Edited by: F Bagnoli, R Rappuoli (2015) • Shigella: Molecular and Cellular Biology www.caister.com/vaccines Edited by: WD Picking, WL Picking (2016) www.caister.com/shigella • Antifungals: From Genomics to Resistance and the Development of Novel Agents • Aquatic Biofilms: Ecology, Water Quality and Wastewater Edited by: AT Coste, P Vandeputte (2015) Treatment www.caister.com/antifungals Edited by: AM Romaní, H Guasch, MD Balaguer (2016) www.caister.com/aquaticbiofilms • Bacteria-Plant Interactions: Advanced Research and Future Trends Edited by: J Murillo, BA Vinatzer, RW Jackson, et al. (2015) • Alphaviruses: Current Biology www.caister.com/bacteria-plant Edited by: S Mahalingam, L Herrero, B Herring (2016) www.caister.com/alpha • Aeromonas Edited by: J Graf (2015) • Thermophilic Microorganisms www.caister.com/aeromonas Edited by: F Li (2015) www.caister.com/thermophile • Antibiotics: Current Innovations and Future Trends Edited by: S Sánchez, AL Demain (2015) www.caister.com/antibiotics • Leishmania: Current Biology and Control Edited by: S Adak, R Datta (2015) www.caister.com/leish2 • Acanthamoeba: Biology and Pathogenesis (2nd edition) Author: NA Khan (2015) www.caister.com/acanthamoeba2 • Microarrays: Current Technology, Innovations and Applications Edited by: Z He (2014) www.caister.com/microarrays2 • Metagenomics of the Microbial Nitrogen Cycle: Theory, Methods and Applications Edited by: D Marco (2014) www.caister.com/n2 Order from caister.com/order 208 Rogers et al. Table 2. Drug Sensitivity of ABC and PDR Deletants ANTICANCER daunorubicin + - - + + + ∆PDR5 ∆SNQ2 ∆YOR1 ∆PDR5 ∆PDR5 ∆PDR1 doxorubicin + - + + + + ∆SNQ2 ∆SNQ2 ∆PDR3 trifluoperazine + - - - - - ∆YOR1 FLAVONOIDS baicalein + + + + + + FUNGICIDES fisetin - - + - + + Azoles myricetin - - + - + + bitertanol + - - + + + quercetin - - + - + + diclobutrazol + - - + + + IONOPHORES flusilazole + - - + + + FCCP - +/- + - + - imazalil nitrate + + + + + + A23187 + + - + + + itraconazole + +/- - + + + monensin + - - - + + ketoconazole + +/- - + + + nigericin + - - +/- + + prochloraz + - - + + + valinomycin + - + - - + tebuconazole + - - + + + ANILINES triadimenol + - - + + + aniline +/- - + + + +/- miconyole +/- +/- + + + +/- p-aminopdiphenylamine - - - + + - expoxiconyole + - + + + + p-amino-p-methoxy- - +/- - - + - triadimylonb + +/- - + + + diphenylamine Imidothiazole phenylhydrazine
Recommended publications
  • Original Article Interaction of Candida Albicans with Fluconazole
    International Journal of Medical Laboratory 2020;7(2):110-120. Original Article Interaction of Candida albicans with Fluconazole/ Clotrimazole: Effect on Hyphae Formation and Expression of Hyphal Wall Protein 1 Sakineh Jam Shahriari1 M.Sc., Fahimeh Alizadeh1* Ph.D. Alireza Khodavandi2 Ph.D. 1Department of Microbiology, Yasooj Branch, Islamic Azad University, Yasooj, Iran. 2Department of Biology, Gachsaran Branch, Islamic Azad University, Gachsaran, Iran. A B S T R A C T Article history Background and Aims: Candida albicans (C. albicans) is the most common Received 20 May 2019 opportunistic human pathogen. Therapeutic options for Candida infections are Accepted 22 Jul 2019 limited to available antifungal drugs. The aim of this study was to investigate Available online 30 May 2020 the effects of fluconazole/clotrimazole (FLU/CLT) on C. albicans hyphae Key words formation. Candida albicans Materials and Methods: We have established the effectiveness of the Clotrimazole combination of FLU/CLT on C. albicans hyphae formation. Interaction of C. Fluconazole Hyphae albicans with combination of FLU/CLT was performed using the CLSI guidelines and time-killing curves. We investigated the anti-hyphal activities of combination of FLU/CLT against C. albicans using XTT and crystal violet assays as well as scanning electron microscopy and expression of HWP1 gene. Results: The interaction of C. albicans with FLU/CLT resulted in synergistic, partial synergistic and indifferent effects. The interaction of FLU/CLT were confirmed by time-killing curves. FLU/CLT combined resulted in the reduction of metabolic activity and hyphae formation in C. albicans. Images taken by scanning electron microscopy indicated the effectiveness on hyphae disruption.
    [Show full text]
  • Eczema Low Cost (TALC) David Chandler 13 in the Community Najeeb Ahmad Safdar & Jane Sterling 6 ABSTRACTS ESSENTIAL DRUGS in DERMATOLOGY Journal Extracts and 1
    An International Journal for Community Skin Health EDITORIAL: PUBLIC HEALTH AND SKIN DISEASE R J Hay DM FRCP record which is often unrecognised. For International Foundation of instance, in the early part of the twenti- Dermatology eth century many countries had policies Professor of Dermatology for the control of scalp ringworm which Faculty of Medicine and Health Sciences ranged from school exclusion orders to special treatment facilities. It resulted in Queen’s University, Belfast, UK partial control but, in the absence of an effective remedy, elimination remained ost of the work of dermato- a distant goal. With the discovery of logists is concerned with the drug, griseofulvin, the potential to the treatment of individ- provide a wider programme based on Mual patients to the highest standards the treatment of communities became achievable with the facilities and skills possible and, in some areas, there was a available. However, it is seldom possible concerted effort to eliminate tinea capi- to apply this to large populations in tis using control teams. Afghan refugee child most parts of the developing world, par- Yaws and leprosy are further exam- ticularly where the lack of resources and ples of diseases where control measures, sparse populations make the adoption of backed by international collaboration, this model of health care unattainable. have focused on elimination of infection In assessing the needs for these groups a by early identification of cases and con- different approach is necessary. tacts and mass drug treatment. Public Health and Skin Skin Disease and the Western Disease World Dermatological public health has sel- In recent years, the focus of public dom been prioritised as a key objec- health in 'western world' dermatology tive in the overall management of has concentrated on the control of the At a Health Centre, Afgooye, Somalia skin diseases, although it has a strong modern epidemic of a non-infectious Photos: Murray McGavin CONTENTS J Comm Dermatol 2005; 2: 1–16 Issue No.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Antifungal Drugs
    Antifungal Drugs Antifungal or antimycotic drugs are those agents used to treat diseases caused by fungus. Fungicides are drugs which destroy fungus and fungistatic drugs are those which prevent growth and multiplication of fungi. Collectively these drugs are often referred to as antimycotic or antifungal drugs. General characteristics of fungus: Fungi of medical significance are of two groups: Yeast Unicellular (Candida, Crytococcus) Molds Multicellular; filamentous consist of hyphae (Aspergillus, Microsporum, Trichophyton) They are eukaryotic i.e. they have well defined nucleus and other nuclear materials. They are made of thin threads called hyphae. The hyphae have a cell wall (like plant cells) made of a material called chitin. The hyphae are often multinucleate. They do not have chlorophyll, can’t make own food by photosynthesis, therefore derive nutrients by means of saprophytic or parasitic existence. Cell membrane is made up of ergosterol. Types of fungal infections: Fungal infections are termed as mycoses and in general can be divided into: Superficial infections: Affecting skin, nails, scalp or mucous membranes; e.g. Tinea versicolor Dermatophytosis: Fungi that affect keratin layer of skin, hair and nail; e.g. Tinea pedis, rign worm infection. Candidiasis: Yeast infections caused by (Malassezia pachydermatis), oral thrush (oral candidiasis), vulvo-vaginitis, nail infection. Systemic/Deep infections: Affecting deeper tissues and organ they usually affect lungs, heart and brain leading to pneumonia, endocarditis and meningitis. Systemic infections are associated with immunocompromised patients, these diseases are serious and often life threatening due to the organ involved. Some of the serious systemic fungal infections in man are candidiasis, cryptococcal meningitis, pulmonary aspergillosis.
    [Show full text]
  • Topical Salicylic Acid and Lactic Acid Microemulsion
    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Research Article Organic & Medicinal Chem IJ Volume 2 Issue 3 - May 2017 DOI: 10.19080/OMCIJ.2017.02.555587 Copyright © All rights are reserved by Maher Aljamal Topical Salicylic acid and Lactic acid Microemulsion Maher Aljamal1,2*, Ibrahim Kayali2 and Mohammad Abul-Haj2 1BeitJala Pharmaceutical Company / Research and Development department, Palestine 2Department of Chemistry, Palestine, Al- Quds university, Israel Submission: April 26, 2017; Published: May 02, 2017 *Corresponding author: Maher Aljamal, BeitJala Pharmaceutical Company / Research and Development department, Al- Quds university, Palestine, Tel: ; Email: Abstract Microemulsionsare used to solubilizing and improve an active pharmaceutical ingredientssolubility and permeability, such as those for topical absorption availability. The objective of this study was to prepare a microemulsion liquid composed of 12% salicylic acid and 4% of lactic acid using castor oil, Tween 80, propylene glycol, ethyl alcohol and purified water. Using the low energy emulsification technique; four andpseudo transparent/translucent ternary phase diagrams microemulsion. were constructed The Resultsand studied indicate for ata leastclear, 75thermodynamic days under a titrationmicroemulsion method liquid using obtainedpurified waterin each (with of the or without propylene glycol), each phase diagram was investigated at 25°C, 37°C and 45°C. The phases include conventional emulsion, viscous using low concentration of Tween 80. It was suggested that microemulsions of 12% Salicylic acid and 4% Lactic acid could be a suitable vehicleconstructed for topical phase treatment diagrams ofat psoriasis, all temperatures scaly patches, of study. ichthyoses, Using propylene dandruff, glycol corns, as calluses, a co-surfactant, and wartson lead the to handsmore orstable feet.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Antifungal and Antibiotic Powders
    ANTIFUNGAL AND ANTIBIOTIC POWDERS Antifungals: Econazole Powder, Ketoconazole Powder, Nyamyc (nystatin) Powder, Nystop (nystatin) Powder Antibiotics: Mupirocin Powder, Tobramycin Powder, Vancomycin Powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy powder products have the potential for misuse. Misuse of these powder products is quite common and it is important to inform patients about the possible complications due to overuse of these drugs. Regulatory Status FDA approved indication: Antifungal agents kill fungi or inhibit their growth. Antifungals that kill fungi are called fungicidal while those that inhibit their growth are called fungistatic. Antibiotics, or antimicrobials, are medications that destroy or slow down the growth of bacteria.
    [Show full text]
  • Sodium Salicylate Influences the Pseudomonas Aeruginosa Biofilm
    International Journal of Molecular Sciences Article Sodium Salicylate Influences the Pseudomonas aeruginosa Biofilm Structure and Susceptibility Towards Silver Erik Gerner 1,2,3,* , Sofia Almqvist 2 , Peter Thomsen 1 , Maria Werthén 1,3 and Margarita Trobos 1,3,* 1 Department of Biomaterials, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden; [email protected] (P.T.); [email protected] (M.W.) 2 Mölnlycke Health Care AB, 415 02 Gothenburg, Sweden; sofi[email protected] 3 Center for Antibiotic Resistance Research (CARe), University of Gothenburg, 405 30 Gothenburg, Sweden * Correspondence: [email protected] (E.G.); [email protected] (M.T.) Abstract: Hard-to-heal wounds are typically infected with biofilm-producing microorganisms, such as Pseudomonas aeruginosa, which strongly contribute to delayed healing. Due to the global challenge of antimicrobial resistance, alternative treatment strategies are needed. Here, we investigated whether inhibition of quorum sensing (QS) by sodium salicylate in different P. aeruginosa strains (QS-competent, QS-mutant, and chronic wound strains) influences biofilm formation and tolerance to silver. Biofilm formation was evaluated in simulated serum-containing wound fluid in the presence or absence of sodium salicylate (NaSa). Biofilms were established using a 3D collagen-based biofilm model, collagen coated glass, and the Calgary biofilm device. Furthermore, the susceptibility of 48-h-old biofilms formed by laboratory and clinical strains in the presence or absence of NaSa towards silver was evaluated by assessing cell viability. Biofilms formed in the presence of NaSa were more susceptible to silver and contained reduced levels of virulence factors associated with biofilm development than those formed in the absence of NaSa.
    [Show full text]
  • Laboratory Analysis Showed That Econazole and Miconazole
    laboratory analysis showed that econazole and Moorfields Eye Hospital miconazole had identical minimal inhibitory City Road London EC 1V 2PD, UK concentrations (0.25 mg/ml), and as econazole is less [email protected] toxic to corneal epithelium when used long-term,13 it was our agent of choice. If possible, pharmacological treatment should be Sir, combined with debridement and removal of necrotic tissue as this speeds recovery and improves final Conservative management of double penetrating ocular outcome.3 Antifungal treatment needs to be continued in injuries the long term after the infection has clinically resolved as Penetrating eye injuries can result in severe visual loss.1 fungal hyphae can persist in tissue several months after Double penetrating (perforating) injuries represent a obtaining negative microbiology swabs.14 separate group which generally have a poorer prognosis?-4 Various surgical options are available to The authors would like to thank Dr jane Leach of the deal with perforating eye injuries. Beneficial effects of microbiology department at Kingston Hospital for her help in vitrectomy in the management of perforating eye injuries the presentation of this case. have been reported,4 and scleral bucklingS,6 procedures with or without intravitreal gas injection also have a role References in the management of perforating eye injuries. We present two cases of double penetrating eye injuries 1. Rippon jW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: Saunders, caused by slender sharp-tipped objects which were 1988. successfully managed conservatively. 2. McGuire TW, Bullock jO, Bullock jO jR, Elder BL, Funkhouser JW. Fungal endophthalmitis: an experimental study with a review of 17 human ocular cases.
    [Show full text]
  • Theranostics CPX Targeting DJ-1 Triggers ROS-Induced Cell Death and Protective Autophagy in Colorectal Cancer
    Theranostics 2019, Vol. 9, Issue 19 5577 Ivyspring International Publisher Theranostics 2019; 9(19): 5577-5594. doi: 10.7150/thno.34663 Research Paper CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer Jing Zhou1,2*, Lu Zhang2*, Meng Wang2*, Li Zhou2, Xuping Feng2, Linli Yu1, Jiang Lan2, Wei Gao2, 1 1 2 3 1 Chundong Zhang , Youquan Bu , Canhua Huang , Haiyuan Zhang , Yunlong Lei 1. Department of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, 400016, P.R.China 2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, P.R. China 3. Key Laboratory of Tropical Diseases and Translational Medicine of Ministry of Education & Department of Neurology, the First Affiliated Hospital of Hainan Medical University, Haikou, P. R. China *These authors contributed equally to this work. Corresponding author: Prof. Yunlong Lei, Department of Biochemistry and Molecular Biology, and Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, P. R. China. Tel: +86 13648323625, Email: [email protected], [email protected]; Prof. Haiyuan Zhang, Key Laboratory of Tropical Diseases and Translational Medicine of Ministry of Education & Department of Neurology, the First Affiliated Hospital of Hainan Medical University, Haikou, P. R. China. Tel: + 86 15027037562, Email: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • Liposomal Amphotericin B Shows Poor Antifungal Activity Against Candida Tropicalis Biofilms L.J
    Liposomal amphotericin B shows poor antifungal activity against Candida tropicalis biofilms L.J. Marcos- Zambrano1,2 ,P. Escribano1,2,3, E. Bouza1,2,3,4, J. Guinea1,2,3,4 EP0063 1 Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 3 CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain. 4 Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid INTRODUCTION RESULTS Candidemia caused by Candida tropicalis present high mortality rates and is often associated with biofilm formation Most of isolates were classified as high- The three drugs showed activity against the isolates in planktonic form, with on implanted medical devices. biofilm forming according to crystal violet micafungin showing the highest activity (P<0.001). Echinocandins and amphotericin B have shown potent in assay (83%) and showed moderate L-AmB showed the lowest antibiofilm activity (P<0.05). MYC and AmB showed similar vitro antibiofilm activity against C.albicans biofilm, but little is metabolic activity (56%) according to activity when the SMIC50 endpoint was used whereas MYC was the most active agent known about the activity against C. tropicalis biofilms. XTT reduction assay. when the SMIC80 endpoint was used (P<0.001). OBJECTIVE Table 1. Antifungal activity of MYC, AmB and L-AmB against C. tropicalis isolates in plancktonic and sessile forms; SMIC and SMIC are provided for the latter forms. We studied the biofilm production and antifungal 50 80 susceptibility of 54 C. tropicalis isolates causing candidemia (2007 to 2015) to micafungin, amphotericin B, and liposomal Planktonic MIC (mg/L) SMIC50 (mg/L) SMIC80 (mg/L) amphotericin B (Ambisome ®) MYC AmB L-AmB MYC AmB L-AmB MYC AmB L-AmB METHODS Geometric mean 0.026 0.53 0.22 0.72 0.87 1.80 9.82 14.07 30.39 54 C.
    [Show full text]